Please login to the form below

Not currently logged in
Email:
Password:

companion diagnostic

This page shows the latest companion diagnostic news and features for those working in and with pharma, biotech and healthcare.

Liver specialist Genfit files $120m IPO on Nasdaq

Liver specialist Genfit files $120m IPO on Nasdaq

Funds will go towards NASH candidate, a companion diagnostic and a liver disease drug. ... diagnostic for NASH to identify patients suitable for treatment with its drug, with another $6m set aside for testing the drug in combination regimens.

Latest news

More from news
Approximately 1 fully matching, plus 54 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    At the moment there is no companion diagnostic for NTRK fusions so patients need to be identified through genomic profiling techniques such as immunohistochemistry or genetic sequencing approaches, which tend to

  • Harnessing complexity Harnessing complexity

    This delicate balance between companion diagnostics' clinical utility and their potential confounding impact on patient treatment is a growing dilemma. ... Answering this question in full requires a scientific journey to better understand what a

  • Diagnostics are rising up the pharma value chain Diagnostics are rising up the pharma value chain

    Diagnostic drivers. It's not just this idea of changing public attitudes that is creating renewed interest in the diagnostics sector; the sector is also influenced by the wider forces affecting ... GlaxoSmithKline and Boehringer Ingelheim have had

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    50. NanoString Technologies/ Celgene. Development. Development of a companion diagnostic assay.

  • Pharma deals during June 2014 Pharma deals during June 2014

    a deal with NanoString Technologies for the development of a companion diagnostic assay to support the development of Revlimid for treatment of Diffuse Large B-Cell Lymphoma at a more modest

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Mastering the precision medicine opportunity

    Novartis and Roche are two champions of personalised medicine, shaping the area with the launch of targeted treatments combined with a companion diagnostic to support patient identification. ... approval of their new  FoundationOne CDx, the first and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics